The Prostate Cancer Biorepository Network (PCBN) is an open resource supported by the Department of Defense (DOD) Prostate Cancer Research Program. We encourage the extensive and appropriate use of our material and welcome applications from academic and private industry scientists (although for-profit entities are not intended as our primary market).
We have implemented a standardized mechanism, based on four principles, for the release and use of material to promote the goals of the network as well as safeguard the interests of our participants.
The following principles guide PCBN in processing applications and releasing material to prostate cancer researcher.
Researcher Access to Material
Requests first go through an initial triage to ensure that the requested samples are available, and that the specimens requested are commensurate with the aims of the research, i.e. smaller numbers of less rare specimens with little or no clinical data for early stage research (discovery, assay optimization), larger numbers of more valuable specimens with long term follow-up data for validation research (e.g. evaluating a prognostic marker already shown to be associated with Gleason score). These distinctions are indicated by the specimen priority levels. See “Prioritization of Access” below. Potential discrepancies are clarified with the Investigator prior to forwarding the request on to the Specimen Request Review Committee. Access is only granted after review by the Specimen Request Review Committee. Disbursed material are not associated with any identifying information.
Members of the Specimen Request Review Committee (full committee) include:
Bruce J Trock, Ph.D. Johns Hopkins University, Baltimore MD (Professor of Urology, Epidemiology, Oncology, Environmental Health)
Jonathan Melamed, M.D. New York University, New York NY (Associate Professor of Pathology)
Bettina F. Drake, Ph.D. MPH Washington University School of Medicine (Assistant Professor of Surgery, Division of Public Health Sciences)
Colm Morrissey, Ph.D. University of Washington (Research Associate Professor of Urology)
Review of applications are standardized and equitable, by a committee with adequate representation from academic research community and is designed to ensure rapid turnaround of requests.
Prioritization of Access
Access to and distribution of PCBN material has been prioritized according to rarity or research value.
|Priority 1||Priority 2||Priority 3|
|TMA: 8 Case Test||TMA: 80 Case Grade/Stage||TMA: 235 Case Natural History of Prostate Cancer*|
|TMA: 10 Case Test PSA Progression||TMA: 200 Case Grade/Stage||TMA: 726 Case PSA Progression*|
|TMA: 40 Case Screening||TMA: 56 Case Hormone Sensitivity||TMA: 217 Case Biochemical Recurrence|
|TMA: Fixation||TMA: 343 Case Family History||TMA: 150 Case Race Disparity*|
|TMA: Ischemia/Fixation Delay||TMA: 119 Case HGPIN||TMA: 114 Case Race Disparity|
|TMA: 50 Case BPH||TMA: 136 Case Zone of Origin*||TMA: 27 Case Lymph Node Mets*|
|TMA: 26 LuCaP PDX Models*||TMA: 320 Case Enrichment*||TMA: 52 Case Lymph Node Mets*|
|TMA: 900 Case Radical Prostatectomy*|
|TMA: 140 Case Genomic*|
|TMA: 45 Case Bone and Visceral Metastasis from Rapid Autopsy*|
|TMA: 20 Case Bone and Visceral Metastasis from Rapid Autopsy*|
|TMA: 15 Metastasis from Rapid Autopsy*|
|Frozen Tissue (<10 samples), no clinical data||Frozen Tissue, with clinical data but not recurrence or outcomes data||Frozen Tissue, large sample size (>25 samples), and/or linked to recurrence or outcomes data|
|FFPE Tissue (<20 samples), no clinical data||FFPE Tissue, with clinical data but not recurrence or outcomes data||FFPE Tissue, large sample size (>100), and/or linked to recurrence or outcomes data|
|DNA/RNA/protein (<20 samples), no clinical data||DNA/RNA/protein, with clinical data but not recurrence or outcomes data||DNA/RNA/protein, large sample size (>50 samples), and/or linked to recurrence or outcomes data||Blood Components (serum, plasma, buffy coat) (<20 samples), no clinical data||Blood Components (serum, plasma, buffy coat), with clinical data but not recurrence or outcomes data||Blood Components (serum, plasma, buffy coat),large sample size (>100 samples), and/or linked to recurrence or outcomes data|
|Prostatic / Seminal Vesicle Fluids (<20 samples), no clinical data||Prostatic / Seminal Vesicle Fluids, with clinical data but not recurrence or outcomes data||Prostatic / Seminal Vesicle Fluids, large sample size (>100 samples) and/or linked to recurrence or outcomes data|
* These TMAs were developed by other investigators prior to the establishment of the PCBN, and using funds from sources other than the PCBN. Because of this substantial investment of investigator time and resources, use of these TMAs may require some collaboration between the applicant requesting the TMA and the originator of the TMA. Whether a collaboration is required will be determined after discussion with the applicant for the TMA, the PCBN Director, and the originator of the TMA. No intellectual property of the applicant (e.g. study hypothesis, biomarker of interest) will be revealed to the originator of the TMA without the permission of the applicant. The nature of the collaboration (if collaboration is required) may range from acknowledgement in a manuscript or conference presentation, co-authorship of a manuscript, or input on study design or analysis, and will be determined by agreement among the involved parties. This policy will have minimal impact on the speed with which the applicant can receive the samples, and can potentially provide the applicant with the benefit of the originator’s research experience with the particular TMA.
A Material Transfers Agreement has been established between the Technology Transfer Offices of the coordinating and network sites, while a Uniform Biological Material Transfer Agreement (UBMTA) is in use to transfer tissue and information.
To view an example of the required analytical validation of antibodies for IHC assays, please see the following file: Form_Redacted.pdf.
Please read through our access policy carefully and familiarize yourself with our requirements prior to completing and submitting an application.